PDF(Pubmed)
Abstract：
Gefitinib is an epidermal growth factor tyrosine kinase inhibitor used as a targeted chemotherapeutic agent in the treatment of lung cancer and other solid malignancies. The most common adverse effects of gefitinib include dermatological side effects and gastrointestinal symptoms, with rare reports of vascular side effects such as myocardial infarction and stroke. We recently reported a case of a patient with diabetes and multiple comorbidities who developed a serious lower limb vascular adverse event after gefitinib treatment, ultimately leading to amputation surgery. This is the first reported case of lower extremity amputation following gefitinib therapy in a patient with type 2 diabetes mellitus and lung adenocarcinoma. This case highlights the potential risk of amputation in diabetic patients receiving targeted therapies like gefitinib, especially in those with vascular complications. It emphasizes the importance of exercising extra caution when dealing with these patients.
摘要：
吉非替尼是一种表皮生长因子酪氨酸激酶抑制剂，用作肺癌和其他实体恶性肿瘤的靶向化疗药物。吉非替尼最常见的不良反应包括皮肤副作用和胃肠道症状。罕见的血管副作用报道，如心肌梗塞和中风。我们最近报道了一例患有糖尿病和多种合并症的患者，在吉非替尼治疗后出现严重的下肢血管不良事件，最终导致截肢手术。这是首例2型糖尿病和肺腺癌患者吉非替尼治疗后下肢截肢的报道。该病例强调了接受吉非替尼等靶向治疗的糖尿病患者截肢的潜在风险。尤其是那些有血管并发症的患者。它强调了在处理这些患者时格外小心的重要性。
